GCP
TVRD

GSA Capital Partners’s Tvardi Therapeutics TVRD Stock Holding History

GSA Capital Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34K Buy
+17,885
New +$56.1K ﹤0.01% 1675
2024
Q2 		– Sell
-1,257
Closed -$41K – 2096
2024
Q1 		$41K Sell
1,257
-4,998
-80% -$130K ﹤0.01% 1541
2023
Q4 		$167K Buy
+6,255
New +$259K 0.01% 1357
2023
Q3 		– Sell
-2,269
Closed -$231K – 1989
2023
Q2 		$231K Buy
2,269
+1,643
+262% +$226K 0.02% 1191
2023
Q1 		$111K Buy
+626
New +$210K 0.01% 1347
2022
Q3 		– Sell
-3,348
Closed -$1.1M – 1933
2022
Q2 		$1.1M Buy
3,348
+2,999
+859% +$1.05M 0.17% 107
2022
Q1 		$153K Buy
+349
New +$143K 0.02% 1230
2019
Q4 		– Sell
-474
Closed -$312K – 1782
2019
Q3 		$312K Buy
+474
New +$394K 0.04% 863
2016
Q4 		– Sell
-1,089
Closed -$327K – 2003
2016
Q3 		$327K Buy
+1,089
New +$236K 0.02% 1311
2016
Q2 		– Sell
-1,556
Closed -$348K – 1954
2016
Q1 		$348K Sell
1,556
-974
-38% -$291K 0.02% 1227
2015
Q4 		$1.53M Buy
2,530
+577
+30% +$317K 0.08% 399
2015
Q3 		$1M Buy
+1,953
New +$1.31M 0.05% 620
2015
Q1 		– Sell
-294
Closed -$106K – 2237
2014
Q4 		$106K Sell
294
-256
-47% -$82.4K 0.01% 1583
2014
Q3 		$166K Buy
+550
New +$226K 0.01% 1559

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

GSA Capital Partners's TVRD Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 17,885 shares worth $34K. The stake represents ﹤0.01% of the portfolio and ranks #1675 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in TVRD as recently as Q1 2024.

GSA Capital Partners first reported a position in TVRD in Q3 2014 and has held it in 14 quarters since. The position peaked at $1.53M in Q4 2015. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • GSA Capital Partners held 17,885 shares of Tvardi Therapeutics worth $34K as of Q2 2026.
  • Tvardi Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1675 holding.
  • GSA Capital Partners first reported a position in Tvardi Therapeutics in Q3 2014 and has held it in 14 quarters since.
  • GSA Capital Partners's Tvardi Therapeutics position peaked at $1.53M in Q4 2015.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.